SyntekaBio, Inc. (KOSDAQ:226330)

Market Cap	106.66B
Revenue (ttm)	983.48M
Net Income (ttm)	-13.53B
Shares Out	15.26M
EPS (ttm)	-886.84
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	66,546
Average Volume	108,352
Open	6,800.00
Previous Close	6,730.00
Day's Range	6,710.00 - 6,960.00
52-Week Range	4,195.00 - 9,430.00
Beta	0.47
RSI	44.34
Earnings Date	Aug 14, 2025

About SyntekaBio

SyntekaBio, Inc. operates as an artificial intelligence new drug development company based on genomic big data primarily in South Korea. It derives new drug candidates using DeepMatcher, an AI drug development platform that combines new drug development technology and genomic big data technology. The company also researches and develops biomarker detection for individual cancer drug screening, disease susceptibility, immune typing, pharmacogenomic typing, and multi-omics information-based drug side effect prediction technology. The company was ...

• Industry: Computer Programming, Data Processing, And Other Computer Related Services
• Founded: 2009
• Country: South Korea
• Stock Exchange: KOSDAQ
• Ticker Symbol: 226330

Financial Performance

In 2024, SyntekaBio's revenue was 120.89 million, a decrease of -2.04% compared to the previous year's 123.41 million. Losses were -7.21 billion, -36.71% less than in 2023.